1xbet 우회., Ltd.
UCB Japan Co., 1xbet 우회.

• E Keppra^®IV Drip Infusion received marketing authorization in Japan last month as an adjunctive therapy 1xbet 우회 partial-onset seizure in epilepsy patients. An application 1xbet 우회 use as monotherapy has now also been submitted.
• Since approximately 70% of patients can live seizure-free lives if they are able to continuously take anti-epileptic drugs, development of injectable 1xbet 우회mulations that can be administered to patients who have difficulty swallowing oral drugs has been desired.
• Launched in Japan in 2010, E Keppra^®has already been used in approximately 100,000 patients and attained the top market share 1xbet 우회 anti-epileptics in Japan.^*1It has been approved 1xbet 우회 use in more than 100 countries and regions and is prescribed to a wide range of patients from children to the elderly. Injectable 1xbet 우회mulations were first approved in Europe and the US in 2006 and have been approved in over 40 countries and regions.

1xbet 우회., Ltd. (headquarters: Tokyo; President and Representative Director: Taro Iwamoto;) and UCB Japan Co., Ltd. (headquarters: Tokyo; President and Representative Director: Joel Peterson) filed an application for partial changes in marketing authorization of E Keppra^®1xbet 우회 IV Drip Infusion 500 mg (levetiracetam) in Japan in order to add an indication of monotherapy 1xbet 우회 partial-onset seizures (including secondary generalized seizures) in epilepsy patients.

• *1©IMS Health, JPM, April-June 2014. Prior permission required 1xbet 우회 use.